These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 19576353)

  • 81. Effect of pioglitazone on systemic inflammation is independent of metabolic control and cardiac autonomic function in patients with type 2 diabetes.
    Nerla R; Pitocco D; Zaccardi F; Scalone G; Coviello I; Mollo R; Ghirlanda G; Lanza GA; Crea F
    Acta Diabetol; 2010 Dec; 47 Suppl 1():117-22. PubMed ID: 19787290
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Do people with diabetes need statins?
    White JR
    Diabetes Educ; 2008; 34(4):664-73. PubMed ID: 18669808
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
    Aliabadi AZ; Mahr S; Dunkler D; Grömmer M; Zimpfer D; Wolner E; Grimm M; Zuckermann AO
    Transplantation; 2008 Dec; 86(12):1771-6. PubMed ID: 19104420
    [TBL] [Abstract][Full Text] [Related]  

  • 85. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.
    Keidar S; Guttmann H; Stam T; Fishman I; Shapira C
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1192-4. PubMed ID: 17636555
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone.
    Abbasi F; Lima NK; Reaven GM
    Metabolism; 2009 Mar; 58(3):373-8. PubMed ID: 19217454
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Lipid lowering in diabetes mellitus.
    Betteridge DJ
    Curr Opin Lipidol; 2008 Dec; 19(6):579-84. PubMed ID: 18957880
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
    Shetty C; Balasubramani M; Capps N; Milles J; Ramachandran S
    Diabet Med; 2007 Jan; 24(1):94-7. PubMed ID: 17227331
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
    Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S
    Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
    Erdmann E; Spanheimer R; Charbonnel B;
    J Diabetes; 2010 Sep; 2(3):212-20. PubMed ID: 20923486
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia.
    López V; Gutiérrez C; Gutiérrez E; Sola E; Cabello M; Burgos D; González Molina M
    Transplant Proc; 2008 Nov; 40(9):2925-6. PubMed ID: 19010149
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting.
    Sathyapalan T; Atkin SL; Kilpatrick ES
    Diabet Med; 2008 Aug; 25(8):909-15. PubMed ID: 18959603
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
    Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
    Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus.
    Wang G; Wang X; Zhang Q; Ma Z
    Int J Clin Pract; 2007 Apr; 61(4):552-7. PubMed ID: 17394430
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Improved cardiac function after sirolimus-eluting stent placement in diabetic patients by pioglitazone: combination therapy with statin.
    Ozawa T; Oda H; Oda M; Hosaka Y; Kashimura T; Ozaki K; Tsuchida K; Takahashi K; Miida T; Aizawa Y
    J Cardiol; 2009 Jun; 53(3):402-9. PubMed ID: 19477383
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy.
    Fegan PG; Shore AC; Mawson D; Tooke JE; MacLeod KM
    Diabet Med; 2005 Dec; 22(12):1670-6. PubMed ID: 16401310
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Pioglitazone treatment stimulates circulating CD34-positive cells in type 2 diabetes patients.
    Makino H; Okada S; Nagumo A; Sugisawa T; Miyamoto Y; Kishimoto I; Akie TK; Soma T; Taguchi A; Yoshimasa Y
    Diabetes Res Clin Pract; 2008 Sep; 81(3):327-30. PubMed ID: 18639363
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus.
    Rosenson RS
    Am J Cardiol; 2007 Feb; 99(4A):96B-104B. PubMed ID: 17307062
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients.
    Gastaldelli A; Casolaro A; Ciociaro D; Frascerra S; Nannipieri M; Buzzigoli E; Ferrannini E
    Am J Physiol Endocrinol Metab; 2009 Jul; 297(1):E225-30. PubMed ID: 19417125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.